Ozempic is approved by the FDA for adults with type 2 diabetes to lower blood sugar, along with diet and exercise, reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes who also have heart disease, and lower the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes who also have chronic kidney disease
Phase 1: the 0.25mg starting dose (5 units) Do not expect weight loss during this phase
Relative grip strength improved (strength normalized to body weight)
Perhaps there are other trials underway
Once empty or expired, the Ozempic pens should be properly disposed of
These side effects are most likely to occur when starting Wegovy treatment or after your dose is increased